Johnson & Johnson (NYSE:JNJ) will release earnings for its first quarter before the opening bell on Tuesday, April 14.

Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings of $2.67 per share, down from $2.77 per share in the year-ago period. The consensus estimate for Johnson & Johnson's quarterly revenue is $23.6 billion (it reported $21.89 billion last year), according to Benzinga Pro.

On March 12, Johnson & Johnson announced the FDA approval of TECNIS PureSee Intraocular Lens intended for use in cataract surgery.

Johnson & Johnson shares gained 1.2% to close at $241.30 on Wednesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • RBC Capital analyst Shagun Singh maintained the stock with an Outperform rating with a price target of $255 on March 30, 2026. This analyst has an accuracy rate of 59%.
  • Barclays analyst Matt Miksic maintained the stock with an Equal-Weight rating and raised the price target from $217 to $234 on March 19, 2026. This analyst has an accuracy rate of 64%.
  • Citigroup analyst Joanne Wuensch maintained a Buy rating and increased the price target from $250 to $274 on March 11, 2026. This analyst has an accuracy rate of 70%.
  • JP Morgan analyst Chris Scott maintained the stock with a Neutral rating and raised the price target from $225 to $250 on March 5, 2026. This analyst has an accuracy rate of 65%.
  • Morgan Stanley analyst Terence Flynn upgraded the stock from Equal-Weight to Overweight and boosted the price target from $200 to $262 on Jan. 28, 2026. This analyst has an accuracy rate of 68%.

Considering buying JNJ stock? Here’s what analysts think:

Photo via Shutterstock